EGFR and lung cancer: Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non‐small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient‐derived Organoid Model (OS‐TUMOVASC)